SCHEMBL15674635

SCHEMBL15674635

Oc1ccc(-c2ccc(Cl)cc2)cc1Br

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.65
ALOX15 P16050 2/20 0.48
ESR2 Q92731 5/20 0.45
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
APP P05067 1/20 0.42
CYP19A1 P11511 1/20 0.42
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
MCL1 Q07820 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
AHR P35869 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ALOX12 P18054 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30268624 0.86 ALOX15 (0.62) ALOX5ALOX15ESR2HSD17B10APP
SCHEMBL5028631 0.86 ALOX15 (0.62) ALOX5ALOX15ESR2HSD17B10APP
SCHEMBL9622875 0.82 ALOX5 (0.62) ALOX5ALOX15ESR2APPKMT2A
SCHEMBL3339161 0.82 ALOX15 (0.65) ALOX5ALOX15ESR2HSD17B10APP
SCHEMBL91153 0.81
SCHEMBL29629596 0.81
SCHEMBL1371332 0.80 ALOX5 (0.64) ALOX5ALOX15ESR2HSD17B10APP
SCHEMBL30144854 0.80 ALOX5 (0.64) ALOX5ALOX15ESR2HSD17B10APP
SCHEMBL28708943 0.79 ALOX15 (0.54) ALOX5ALOX15HSD17B10TSHRCYP19A1
SCHEMBL28686760 0.79 ALOX15 (0.54) ALOX5ALOX15HSD17B10TSHRCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2917181-B1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY INC (US) 2019-09-25 EP disclosed
US-9409893-B2 Heteroaryl derivatives and uses thereof JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2016-08-09 US disclosed
EP-2917181-A1 HETEROARYL DERIVATIVES AND USES THEREOF Jacobus Pharmaceutical Company, Inc. (US) 2015-09-16 EP disclosed
WO-2014074775-A1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2014-05-15 WO disclosed
US-20140135320-A1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135320-A1 HETEROARYL DERIVATIVES AND USES THEREOF ABCC1, CYP3A43, ABCB1 ALOX5 1202/4885ALOX15 2197/4885ESR2 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.